Biotech sees a new, hard era ahead, survey finds
Biotech is reeling, fearful and furious about the fallout of tariffs, FDA and NIH policies, says BioCentury’s Risk Sentiment survey
The first half of 2025 may go down as the time when the golden era of biotech gave way to its darkest days in decades. There have been rough periods before, but this one compounds a market collapse with a hollowing out of FDA, the devaluing of scientific research, and the potential decline of U.S. preeminence in biomedical science.
That is the inescapable takeaway from a survey of 328 biopharma stakeholders conducted April 10-14. The responses included 168 (51%) from company executives; 92 (28%) from investors, investment bankers and financial advisers; and 68 from other professionals, including legal and other service providers, CRO/CDMOs, academics; and five regulatory experts. Respondents were primarily from the U.S. (71%) with 21% from Europe, and 7% from APAC and other ex-U.S. regions. ...